Amorphous Solid Dispersion Via Twin-Screw Hot-Melt Extrusion in Immediate-Release Tablet Manufacture

For hemp-derived pharmaceutical-grade Cannabidiol intended for compressed oral tablets, the crystalline API exhibits aqueous solubility below 0.01 mg/mL and a reported log P near 6.3, making direct-compression products vulnerable to dissolution-limited absorption and high fasted-state variability. An amorphous solid dispersion processed by hot-melt extrusion is therefore configured on a co-rotating twin-screw extruder with an L/D ratio between 25:1 and 40:1, using gravimetric loss-in-weight feeders for both API and polymer. The API is preblended with hypromellose acetate succinate or polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer at an API addition ratio of 5–25% w/w and a polymer-to-API ratio of 2:1 to 4:1; an optional plasticizer may be introduced at 0–10% w/w of the polymer fraction to lower melt viscosity. Barrel zone temperatures are maintained between 120 °C and 140 °C, with screw speeds of 200–500 rpm and specific mechanical energy held below the point at which observable degradation products increase; the processing window is narrow because the amorphous phase can recrystallize if the extruder barrel deviates more than ±5 °C from the set zone at the mixing section. The extrudate is cooled on a stainless steel belt, milled through a 0.5 mm screen, and blended with disintegrant, microcrystalline cellulose, and magnesium stearate before compression. Tablet dissolution is tested according to USP <711> Apparatus II at 50 rpm in 900 mL of pH 6.8 phosphate buffer containing 0.5% w/v sodium lauryl sulfate, with acceptance criteria typically requiring not less than 70% dissolved at 45 min. Batch release includes uniformity of dosage units by USP <905>, elemental impurities by ICH Q3D, and in-process sampling under 21 CFR 211.110; pharmaceutical development documentation is aligned with ICH Q8(R2). Finished product types are immediate-release tablets in 10 mg, 25 mg, and 50 mg strengths.

Process failures on 11 mm and 16 mm twin-screw extruders commonly arise from screw torque excursions above 12 N·m per screw when feed rate is increased without matching screw speed, causing localized melt temperature rise and light-brown discoloration. Batch-to-batch variance is reduced by conditioning the API at ≤25 °C and ≤60% RH before gravimetric feeding; residual moisture above 2% w/w in the HME feed suppresses the glass transition of the amorphous phase and can cause melt foaming at the die. Recrystallization at the tablet surface is observed when tablet hardness exceeds 150 N and disintegrant hydration is retarded by the hydrophobic polymer; therefore, croscarmellose sodium at 2–5% w/w of tablet core is recommended rather than corn starch. Avoid combination with acidulants below pH 2.5 in aqueous granulation binders because prolonged acidic contact can increase the formation of degradation-related impurities beyond compendial limits.

When a liquid-filled hard capsule format is selected for bioenhancement, the API is incorporated into a preheated lipid-based matrix rather than subjected to direct powder filling. The fill formulation consists of medium-chain triglycerides, PEG-40 hydrogenated castor oil, and lecithin, with the API dissolved at 2–10% w/w of the total fill mass under nitrogen overlay at 35–45 °C in a jacketed mixing vessel; the addition ratio is limited by recrystallization upon cooling below 25 °C when the API load exceeds approximately 10% w/w. The molten fill is transferred to a piston pump capsule filler, and individual fill weight is controlled to ±3% of target for 25 mg and 50 mg strengths. In-process viscosity is measured with a rotational viscometer at 40 °C, and the acceptable range is 150–400 mPa·s; values above 400 mPa·s produce cavitation in the filling pump and underfilled capsules, while values below 150 mPa·s result in splashing and seal contamination. After filling, capsules are banded or sealed, cooled to 15–25 °C, and inspected for leakers. Release testing includes USP <711> dissolution, USP <905> content uniformity, and ICH Q3D elemental impurities; in-process verification is governed by 21 CFR 211.110. Terminal finished dosage forms are liquid-filled hard capsules in 25 mg and 50 mg strengths. Operational boundaries are explicit: gelatin shells must not be exposed to temperatures above 45 °C for more than 30 min, and HPMC shells require closure with a polymer band rather than heat alone because the fill surface energy can prevent adhesion; storage above 25 °C/60% RH can cause API migration into the shell wall and visible speckling.

What Limits Dose Uniformity in 2 mg/g Pediatric Granule Blends?

Low-dose granule blends for pediatric oral suspension are limited by segregation between the micronized API and soluble diluents, not by chemical stability alone. The target potency in the finished granule is 2 mg/g to 5 mg/g, corresponding to an API addition ratio of 0.2–1.0% w/w on a dry-weight basis. The manufacturing line uses a fluid-bed granulator with a top-spray Wurster column, not a high-shear mixer, because the low drug load requires avoidance of wet mass over-densification. A hypromellose binder solution at 2–5% w/w solids is sprayed at inlet air temperature 55–70 °C, product temperature 30–40 °C, and airflow 80–120 m³/h for a 5 kg batch. The dried granule is sieved to retain 125–500 µm; fines below 75 µm are capped at ≤15% w/w because elutriation of fines in the sachet filling hopper produces assay values below 90.0% label claim. Loss on drying end point is 1.0–2.5% w/w, measured by infrared moisture balance. The granule is filled into sachets using a gravimetric auger filler with fill weight control of ±5% for 500 mg and 1000 mg sachets. Uniformity of dosage units is evaluated according to USP <905> and Ph. Eur. 2.9.40; release testing includes 21 CFR 211.165, stability under 21 CFR 211.166, and elemental impurities per ICH Q3D. The terminal product type is granules for oral suspension, reconstituted to 5 mL or 10 mL in a graduated dosing cup. Incompatibility is documented with acidic flavoring agents below pH 3.5, which can accelerate degradation and shift impurity profiles beyond the specification at the 24-month stability checkpoint.

At production scale, the dominant failure mode occurs when the relative humidity in the granulation suite falls below 30% RH; the micronized API adheres electrostatically to the Wurster filter bag and to the discharge hopper, causing batch assay to drop by 3–5% across sequential sachet filling runs. This is mitigated by humidifying the suite to 40–50% RH and by pre-coating the API with 0.5–1.0% w/w colloidal silicon dioxide before binder spraying. Published data for this specific pediatric granule configuration is limited; the processing ranges are derived from low-dose fluid-bed granulation of lipophilic actives and should be confirmed by development batches.

Parenteral delivery of hemp-derived pharmaceutical-grade Cannabidiol is constrained by an aqueous solubility below 0.01 mg/mL and a strong preference for the oil phase, so the downstream formulation is a sterile oil-in-water nanoemulsion rather than a simple aqueous solution. The oil phase comprises medium-chain triglycerides and egg lecithin at 10–20% w/v, and the API is loaded at 0.05–0.5% w/v in the final emulsion, equivalent to 0.5–5 mg/mL and an API-to-lipid ratio of 1:20 to 1:50. A coarse emulsion is first generated under a nitrogen atmosphere with a high-shear rotor-stator homogenizer at 10,000–20,000 rpm for 5–10 min; the coarse dispersion is then processed through a high-pressure homogenizer at 800–1500 bar for 5–10 discrete passes, with cooling to 5–15 °C between passes to limit thermal input. Droplet size is monitored by dynamic light scattering, with a Z-average target of 80–180 nm and polydispersity index ≤0.15; the emulsion is then diluted to final volume and filtered through a 0.22 µm membrane only after confirming that the oil-phase droplet size distribution will not blind the filter. Terminal sterilization is avoided because of thermal degradation, so aseptic processing under ISO 14644-1 Class 5 is required, supported by 21 CFR 211.113 and USP <1>. Release specifications include USP <85> bacterial endotoxins, USP <71> sterility, USP <788> particulate matter by light obscuration, USP <790> visible particles, and ICH Q3D elemental impurities. The terminal finished product type is an injectable emulsion, typically presented as 10 mg/10 mL vials for intravenous administration. The table below summarizes the critical quality attributes for the injectable nanoemulsion; published data for this specific parenteral Cannabidiol configuration is limited, and the ranges are feasibility targets based on lipophilic parenteral emulsions, not an approved marketed injectable product.

When Low-Dose API-in-Capsule Supplies Are Required for Blinded Clinical Trial Manufacturing

Blinded clinical manufacturing demands dose indistinguishability between active and placebo capsules, which dictates a direct-encapsulation process rather than granulation because granule density differences are visible through opaque HPMC shells after vibration. The API is pre-blended with microcrystalline cellulose and lactose monohydrate at an API addition ratio of 0.1–10% w/w, corresponding to 1 mg to 100 mg per size 3 to size 0 capsule. Geometric dilution is performed in a V-blender at 15–25 rpm in three stages of 10–15 min each; the first stage dilutes API with lactose monohydrate at a 1:10 ratio to overcome electrostatic adhesion, the second stage brings the blend to 30% of final volume, and the third stage completes the batch. Magnesium stearate is added at 0.5% w/w and blended for 3–5 min; over-lubrication is avoided because hydrophobic film formation on API particles retards dissolution in USP <711> Apparatus II. Encapsulation proceeds on an automatic dosator or tamping-pin capsule filler with target fill weight ±3%, and in-process check weights are recorded every 15 min. Disintegration time is tested according to USP <701>, content uniformity by USP <905>, raw material verification under 21 CFR 211.84, release testing under 21 CFR 211.165, and elemental impurities by ICH Q3D. For investigational medicinal product handling, ICH E6(R2) documentation controls are applied to blinding and randomization. The terminal finished product type is low-dose hard capsules in 1 mg, 5 mg, 25 mg, and 50 mg strengths for clinical trial use. The operational boundary is that direct encapsulation of API loads below 0.1% w/w without pre-blending produces assay values outside 90.0–110.0% and is not recommended for blinded comparators.

Batch-to-batch variance in this format is driven primarily by API particle size rather than blend time. Milled API with a D90 above 100 µm shows higher segregation and greater content-uniformity failure rates than micronized material with D90 below 30 µm, but over-micronization below 5 µm increases surface area and accelerates oxidation unless the API is stored under nitrogen and protected from light. Published data specific to hemp-derived pharmaceutical-grade Cannabidiol in blinded low-dose capsules is limited; the ranges described reflect standard pharmaceutical practices for low-dose solid oral investigational products and require development confirmation.

Where Wax-Lipid Granules Are Compacted into 24-Hour Release Matrix Tablets

Prolonged-release matrix tablets are manufactured by melt granulation with wax-lipid binders to reduce the high first-pass variability associated with immediate-release Cannabidiol and to provide twice-daily or once-daily dosing in investigational oral products. The API addition ratio is 5–30% w/w of the dry granule mass; the matrix former is glyceryl behenate at 15–40% w/w, with ethylcellulose or hypromellose K100M as the release-retarding polymer at 5–20% w/w. Melt granulation is performed in a jacketed high-shear granulator at impeller speed 200–400 rpm and chopper speed 1000–2000 rpm, with the jacket set to 60–75 °C; the end point is reached when the wax melts and forms agglomerates of 250–850 µm, and over-granulation beyond 75 °C causes wax migration that destroys the sustained-release matrix structure. The milled granules are blended with magnesium stearate 0.5% w/w and compacted on a rotary tablet press at 15–35 kN, with hardness controlled at 80–150 N. Drug release is tested by USP <711> Apparatus II at 50 rpm in 900 mL of pH 6.8 phosphate buffer with 0.5% w/v sodium lauryl sulfate; release profiles are evaluated at 1 h, 2 h, 4 h, 8 h, 12 h, and 24 h, with a typical target of not more than 30% dissolved at 1 h and not less than 70% dissolved at 24 h. Compliance includes 21 CFR 211.110 in-process controls, 21 CFR 211.166 stability testing, ICH Q3D, and ICH Q1A(R2) stability study design. The terminal finished product type is prolonged-release matrix tablets in 50 mg and 100 mg strengths. Operational boundaries include the incompatibility of glyceryl behenate with high-shear mixing below 60 °C, which produces friable granules below 0.8% friability and capping at the compression stage; published data specific to hemp-derived pharmaceutical-grade Cannabidiol in wax-lipid matrix tablets is limited, and these parameters are solid oral matrix formulation feasibility targets requiring product-specific confirmation.